ArticleAntibiotics (Basel, Switzerland)2021
Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections.
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- Approaching the post-antibiotic era: phage therapy current practices and future horizons.mBio · 2026Review
- Urinary Tract Infections: Etiology and Emerging Therapeutic Approaches.Antibiotics (Basel, Switzerland) · 2026Review
- Hospital-adapted inhaled phage therapy for ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae: a comparative pilot study.Critical care (London, England) · 2026Article
- Harnessing phages in the age of antibiotic resistance: immunological perspectives.Frontiers in immunology · 2026Review
- Clinical and Translational Perspectives on Bacteriophage Therapy for Nontuberculous Mycobacterial Diseases.Journal of microbiology and biotechnology · 2025Review
- Human bladder organoids model urinary tract infection and bacteriophage therapy.bioRxiv : the preprint server for biology · 2025Article
- Phage Therapy for Urinary Tract Infections: Progress and Challenges Ahead.International urogynecology journal · 2025Review
- Phage Therapy: A Promising Treatment Strategy against Infections Caused by Multidrug-resistantCurrent pharmaceutical design · 2025Review
- Review
- Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections.Infectious disease reports · 2024Review
- Interaction of Bacteriophages with the Immune System: Induction of Bacteriophage-Specific Antibodies.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Phage Therapy in the Management of Urinary Tract Infections: A Comprehensive Systematic Review.PHAGE (New Rochelle, N.Y.) · 2023Article
- Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- A Thorough Synthesis of Phage Therapy Unit Activity in Poland-Its History, Milestones and International Recognition.Viruses · 2022Article
- Essential Topics for the Regulatory Consideration of Phages as Clinically Valuable Therapeutic Agents: A Perspective from Spain.Microorganisms · 2022Review
- Biological aspects of phage therapy versus antibiotics againstFrontiers in cellular and infection microbiology · 2022Article
- Potential for Phages in the Treatment of Bacterial Sexually Transmitted Infections.Antibiotics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with chronic urinary and urogenital multidrug resistant bacterial infections received phage therapy (PT) using intravesical or intravesical and intravaginal phage administration. A single course of PT did not induce significant serum antibody responses against administered phage. Whilst the second cycle of PT caused a significant increase in antibody levels, they nevertheless remained quite low. These data combined with good therapy results achieved in some patients suggest that this mode of PT may be an efficient means of therapy for urogenital infections and a reliable model for a clinical trial of PT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.